HSITF:OTC-Hadasit Bio-Holdings Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.13

Change

0.00 (0.00)%

Market Cap

USD 1.44M

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

HBL - Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It operates in the fields of oncology, regenerative medicine, and inflammatory disease. The company develops biological drugs; and plasma RNA biomarkers for colorectal cancer. It offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. HBL - Hadasit Bio-Holdings Ltd was incorporated in 2005 and is based in Jerusalem, Israel.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
UCBJY UCB SA ADR

N/A

USD 34.52B
UCBJF UCB SA

N/A

USD 33.97B
ARGNF argenx SE

N/A

USD 32.04B
GNMSF Genmab A/S

N/A

USD 16.79B
ZLDPF Zealand Pharma A/S

N/A

USD 9.62B
IVBIY IVBIY

N/A

USD 9.33B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 7.86B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 7.85B
WXIBF WuXi Biologics

N/A

USD 7.06B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 7.06B

ETFs Containing HSITF

IAEX:LSE iShares AEX UCITS ETF EUR.. 3.23 % 0.00 %

N/A

N/A
XFI:CA 1.96 % 0.51 %

N/A

N/A
QINT American Century Quality .. 1.09 % 0.00 %

N/A

USD 0.21B
RODM Hartford Multifactor Deve.. 0.97 % 0.31 %

N/A

N/A
MVAE:LSE 0.77 % 0.00 %

N/A

N/A
MVEX:LSE 0.77 % 0.00 %

N/A

N/A
EFAV 0.00 % 0.20 %

N/A

N/A
EWN iShares MSCI Netherlands .. 0.00 % 0.47 %

N/A

N/A
FSEU:LSE iShares Edge MSCI Europe .. 0.00 % 0.00 %

N/A

N/A
IFSD:LSE iShares Edge MSCI Europe .. 0.00 % 0.00 %

N/A

N/A
IBC0:F iShares Edge MSCI Europe .. 0.00 % 0.00 %

N/A

N/A
SPYC:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

N/A
IEEU:LSE iShares Edge MSCI Europe .. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -48.00% 27% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.00% 27% F 19% F
Trailing 12 Months  
Capital Gain -48.00% 36% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.00% 36% F 23% F
Trailing 5 Years  
Capital Gain -93.63% 26% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -93.63% 26% F 15% F
Average Annual (5 Year Horizon)  
Capital Gain 2,623.25% N/A N/A 98% N/A
Dividend Return 2,623.25% N/A N/A 97% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10,343.40% N/A N/A 3% F
Risk Adjusted Return 25.36% N/A N/A 60% D-
Market Capitalization 1.44M 32% F 21% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector